Tomasz Brzozowski

Prof. Tomasz Brzozowski

Department of Physiology, Faculty of Medicine, Jagiellonian University Medical College
orcid

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
Jan BilskiJan Bilski
Jan Bilski
AMAgnieszka Mazur-Bialy
Agnieszka Mazur-Bialy
DWDagmara Wójcik
Dagmara Wójcik
JZJanina Zahradnik-Bilska
Janina Zahradnik-Bilska
Tomasz BrzozowskiTomasz Brzozowski
Tomasz Brzozowski
Tomasz BrzozowskiTomasz Brzozowski
Tomasz Brzozowski
Over the past few years, the role of intestinal alkaline phosphatase (IAP) as a crucial mucosal defence factor essential for maintaining gut homeostasis has been established. IAP is an important apical brush border enzyme expressed throughout the gastrointestinal tract and secreted both into the intestinal lumen and into the bloodstream. IAP exerts its effects through dephosphorylation of proinflammatory molecules including lipopolysaccharide (LPS), flagellin, and adenosine triphosphate (ATP) released from cells during stressful events. Diminished activity of IAP could increase the risk of disease through changes in the microbiome, intestinal inflammation, and intestinal permeability. Exogenous IAP exerts a protective effect against intestinal and systemic inflammation in a variety of diseases and represents a potential therapeutic agent in diseases driven by gut barrier dysfunction such as IBD. The intestinal protective mechanisms are impaired in IBD patients due to lower synthesis and activity of endogenous IAP, but the pathomechanism of this enzyme deficiency remains unclear. IAP has been safely administered to humans and the human recombinant form of IAP has been developed. This review was designed to provide an update in recent research on the involvement of IAP in intestinal inflammatory processes with focus on IBD in experimental animal models and human patients.

31 October 2016 in Current Neuropharmacology
Verified
Journal Article
Open access
BBBartosz Brzozowski
Bartosz Brzozowski
AMAgnieszka Mazur-Bialy
Agnieszka Mazur-Bialy
RPRobert Pajdo
Robert Pajdo
SKSławomir Kwiecień
Sławomir Kwiecień
Jan BilskiJan Bilski
Jan Bilski
Tomasz BrzozowskiTomasz Brzozowski
Tomasz Brzozowski
BACKGROUND: Stress of different origin is known to alter so called “brain-gut axis” and contributes to a broad array of gastrointestinal disorders including inflammatory bowel disease (IBD), irritable bowel syndrome (IBS) and other functional gastrointestinal diseases. The stressful situations and various stressors including psychosocial events, heat, hypo- and hyperthermia may worsen the course of IBD via unknown mechanism. The aims of this paper were to provide an overview of experimental and clinical evidences that stress activates the brain-gut axis which results in a mucosal mast cells activation and an increase in the production of proinflammatory cytokines and other endocrine and humoral mediators. METHODS: Research and online content related to effects of stress on lower bowel disorders are reviewed and most important mechanisms are delineated. RESULTS: Brain conveys the neural, endocrine and circulatory messages to the gut via brain-gut axis reflecting changes in corticotrophin releasing hormone, mast cells activity, neurotransmission at the autonomic nerves system and intestinal bar¬rier function all affecting the pathogenesis of animal colitis and human IBD. Stress triggers the hypothalamus-pituitary axis and the activation of the autonomic nervous system, an increase in cortisol levels and proinflammatory cytokines such as tumor necrosis factor-alpha, interleukin-8, interleukin-1beta and interleukin-6. CONCLUSION: The acute or chronic stress enhances the intestinal permeability weakening of the tight junctions and increasing bacterial translocation into the intestinal wall. An increased microbial load in the colonic tissue, excessive cytokine release and a partially blunted immune reactivity in response to stress result in its negative impact on IBD.

26 November 2019 in Biomolecules
Verified
Journal Article
Open access
PDF file
Jan BilskiJan Bilski
Jan Bilski
AMAgnieszka Mazur-Bialy
Agnieszka Mazur-Bialy
DWDagmara Wójcik
Dagmara Wójcik
MSMarcin Surmiak
Marcin Surmiak
Marcin MagierowskiMarcin Magierowski
Marcin Magierowski
Tomasz BrzozowskiTomasz Brzozowski
Tomasz Brzozowski
Inflammatory bowel diseases (IBDs) are a group of disorders which include ulcerative colitis and Crohn’s disease. Obesity is becoming increasingly more common among patients with inflammatory bowel disease and plays a role in the development and course of the disease. This is especially true in the case of Crohn’s disease. The recent results indicate a special role of visceral adipose tissue and particularly mesenteric adipose tissue, also known as “creeping fat”, in pathomechanism, leading to intestinal inflammation. The involvement of altered adipocyte function and the deregulated production of adipokines, such as leptin and adiponectin, has been suggested in pathogenesis of IBD. In this review, we discuss the epidemiology and pathophysiology of obesity in IBD, the influence of a Western diet on the course of Crohn’s disease and colitis in IBD patients and animal’s models, and the potential role of adipokines in these disorders. Since altered body composition, decrease of skeletal muscle mass, and development of pathologically changed mesenteric white adipose tissue are well-known features of IBD and especially of Crohn’s disease, we discuss the possible crosstalk between adipokines and myokines released from skeletal muscle during exercise with moderate or forced intensity. The emerging role of microbiota and the antioxidative and anti-inflammatory enzymes such as intestinal alkaline phosphatase is also discussed, in order to open new avenues for the therapy against intestinal perturbations associated with IBD.

19 May 2015 in Molecules
Verified
Journal Article
Open access
PDF file
Marcin MagierowskiMarcin Magierowski
Marcin Magierowski
KMKatarzyna Magierowska
Katarzyna Magierowska
SKSławomir Kwiecień
Sławomir Kwiecień
Tomasz BrzozowskiTomasz Brzozowski
Tomasz Brzozowski
Nitric oxide (NO) and hydrogen sulfide (H2S) are known as biological messengers; they play an important role in human organism and contribute to many physiological and pathophysiological processes. NO is produced from l-arginine by constitutive NO synthase (NOS) and inducible NOS enzymatic pathways. This gaseous mediator inhibits platelet aggregation, leukocyte adhesion and contributes to the vessel homeostasis. NO is known as a vasodilatory molecule involved in control of the gastric blood flow (GBF) and the maintenance of gastric mucosal barrier integrity in either healthy gastric mucosa or that damaged by strong irritants. Biosynthesis of H2S in mammals depends upon two enzymes cystathionine-β-synthase and cystathionine γ-lyase. This gaseous mediator, similarly to NO and carbon monoxide, is involved in neuromodulation, vascular contractility and anti-inflammatory activities. For decades, H2S has been known to inhibit cytochrome c oxidase and reduce cell energy production. Nowadays it is generally considered to act through vascular smooth muscle ATP-dependent K+ channels, interacting with intracellular transcription factors and promote sulfhydration of protein cysteine moieties within the cell, but the mechanism of potential gastroprotective and ulcer healing properties of H2S has not been fully explained. The aim of this review is to compare current results of the studies concerning the role of H2S and NO in gastric mucosa protection and outline areas that may pose new opportunities for further development of novel therapeutic targets.

1 August 2004 in Regulatory Peptides
Verified
Journal Article
Closed access
Tomasz BrzozowskiTomasz Brzozowski
Tomasz Brzozowski
PKP.C Konturek
P.C Konturek
SKS.J Konturek
S.J Konturek
SKSławomir Kwiecień
Sławomir Kwiecień
DDD Drozdowicz
D Drozdowicz
EHE.G Hahn
E.G Hahn

1 January 2014 in BioMed Research International
Verified
Journal Article
Open access
PDF file
Jan BilskiJan Bilski
Jan Bilski
BBBartosz Brzozowski
Bartosz Brzozowski
AMAgnieszka Mazur-Bialy
Agnieszka Mazur-Bialy
ZSZbigniew Sliwowski
Zbigniew Sliwowski
Tomasz BrzozowskiTomasz Brzozowski
Tomasz Brzozowski
We reviewed and analyzed the relationship between physical exercise and inflammatory bowel disease (IBD) which covers a group of chronic, relapsing, and remitting intestinal disorders including Crohn’s disease (CD) and ulcerative colitis. The etiology of IBD likely involves a combination of genetic predisposition and environmental risk factors. Physical training has been suggested to be protective against the onset of IBD, but there are inconsistencies in the findings of the published literature. Hypertrophy of the mesenteric white adipose tissue (mWAT) is recognized as a characteristic feature of CD, but its importance for the perpetuation of onset of this intestinal disease is unknown. Adipocytes synthesize proinflammatory and anti-inflammatory cytokines. Hypertrophy of mWAT could play a role as a barrier to the inflammatory process, but recent data suggest that deregulation of adipokine secretion is involved in the pathogenesis of CD. Adipocytokines and macrophage mediators perpetuate the intestinal inflammatory process, leading to mucosal ulcerations along the mesenteric border, a typical feature of CD. Contracting skeletal muscles release biologically active myokines, known to exert the direct anti-inflammatory effects, and inhibit the release of proinflammatory mediators from visceral fat. Further research is required to confirm these observations and establish exercise regimes for IBD patients.